The Ohio State University

Running trials

• Not yet recruiting

  Futibatinib With Paclitaxel and Ramucirumab for the Treatment of Locally Advanced or Unresectable Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma

  NCT07594548· Phase 1· Northwestern University· Source

• Not yet recruiting

  The Hear Clear Study

  NCT07824115· Duke University· Source

• Not yet recruiting

  Peer Support for Family Caregivers of Older Adults Living With Dementia

  NCT07868718· Phase 2· Ohio State University· Source

• Recruiting

  Symptoms of Polycystic Ovarian Syndrome Ameliorated by Keto-Adaptation Pilot

  NCT07227363· Ohio State University· Source

• Recruiting

  SPI-1005 in Adults Receiving Cochlear Implant

  NCT06340633· Phase 2· Sound Pharmaceuticals, Incorporated· Source

• Recruiting

  A Mechanistic Study to Assess a Single Dose of CYB003 in Participants With Depression and Anxiety

  NCT06820723· Phase 2· Ohio State University· Source

• Not yet recruiting

  AAV2-hAADC for Parkinson's Disease (PDCS-01)

  NCT07267065· Phase 1· Russell Lonser· Source

• Recruiting

  Tornier Perform™ Reversed Monopost Study

  NCT07764614· Stryker Trauma and Extremities· Source

• Recruiting

  Fermented Foods and Bowel Health in SCI

  NCT07640152· Ohio State University· Source

• Not yet recruiting

  Gestational Hypertension and Preeclampsia Blood Pressure (BP) Treatment Goals Less Than 140/90 vs. Less Than 160/110 mmHg: The GOALPOST Trial

  NCT07746271· Phase 3· The George Washington University Biostatistics Center· Source

• Recruiting

  MaioRegen Prime Study for the Treatment of Deep Osteochondral Lesion of the Knee

  NCT07332182· Fin-Ceramica Faenza Spa· Source

• Not yet recruiting

  Solving Stigma Through POV Simulation: Enhancing Pharmacist Empathy-based Practices With Sickle Cell Disease Patients

  NCT07217548· Ohio State University· Source

• Recruiting

  Pacritinib Effectiveness in Real-world Settings

  NCT07774455· Swedish Orphan Biovitrum· Source

• Recruiting

  The Study of Chronic Obstructive Pulmonary Disease (COPD) Participants Treated With Dupilumab (STRIDE) Registry

  NCT07612878· Sanofi· Source

• Recruiting

  Self-Supervised Constraint-Induced Movement Therapy for Stroke Recovery

  NCT07723300· Ohio State University· Source

• Recruiting

  A Study of Esketamine Nasal Spray Versus Placebo Spray in Adult Participants With Treatment-resistant Depression

  NCT07716098· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  Metric-Optimized Spectacle Prescriptions for Children With Down Syndrome

  NCT07490444· Phase 2· Ohio State University· Source

• Recruiting

  Pridopidine Phase 3 Study in Huntington's Disease

  NCT07609108· Phase 3· Prilenia· Source

• Recruiting

  A Study With NVC-001 in Patients With LMNA-related Dilated Cardiomyopathy (SUNBEAM-LMNA)

  NCT07606274· Phase 1/2· Nuevocor Pte. Ltd.· Source

• Recruiting

  Determination of Resistance Training Status for Patients on Glucagon-Like Peptide-1 Receptor Agonists

  NCT07702461· Ohio State University· Source

• Recruiting

  Parent-Mediated Telehealth Intervention for Insomnia in Young Autistic Children

  NCT07435740· The Cleveland Clinic· Source

• Not yet recruiting

  An International Multicenter, Multivendor Evaluation of the Free-Running Framework for Cardiac Function

  NCT07613398· Matthias Stuber· Source

• Recruiting

  A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)

  NCT07393282· Phase 3· Regeneron Pharmaceuticals· Source

• Recruiting

  Study of INCA036978 in Participants With Myeloproliferative Neoplasms

  NCT07441694· Phase 1· Incyte Corporation· Source

• Active, not recruiting

  An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)

  NCT07517263· Phase 3· Novartis Pharmaceuticals· Source

• Recruiting

  Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII

  NCT07326566· Phase 2· Black Diamond Therapeutics, Inc.· Source

• Recruiting

  A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

  NCT06769698· Phase 2· Regeneron Pharmaceuticals· Source

• Recruiting

  Safety and Efficacy of Adjunct Therapies in Adults With Type 1 Diabetes: Multicenter, Registry Study

  NCT07676565· Indiana University· Source

• Recruiting

  Stroke Volume-based Fluid Resuscitation in AP

  NCT07756476· University of Southern California· Source

• Recruiting

  Randomized Controlled Trial of Two Mobile Health Strategies to Manage Postpartum Hypertension

  NCT07209254· Jennifer Lewey, MD, MPH· Source

• Recruiting

  A Double-blind, Randomized Controlled Trial to Investigate the Efficacy, Safety, and Pharmacokinetics of Pegloticase Administration Via Subcutaneous and Intravenous Routes Both With Methotrexate in Participants With Uncontrolled Gout

  NCT07388498· Phase 3· Amgen· Source

• Recruiting

  A Study to Assess Adverse Events and Change in Disease Activity of Oral Icalcaprant in Adult Participants With Bipolar I or II Disorder

  NCT06696755· Phase 2· AbbVie· Source

• Recruiting

  Safety of Anumigilimab (CSL324) in Adults With Sickle Cell Disease (SCD)

  NCT07224360· Phase 2· CSL Behring· Source

• Recruiting

  Adjuvant Temozolomide ± 5-Aminolevulinic Acid + Low Intensity Diffuse Ultrasound Sonodynamic Therapy System for Newly Diagnosed Glioblastoma

  NCT07225621· Phase 2· Alpheus Medical, Inc.· Source

• Recruiting

  Zilucoplan for Severe gMG Exacerbations

  NCT07215949· Phase 3· Miriam Freimer· Source

• Recruiting

  Non-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple Sclerosis

  NCT07325292· Phase 3· Sanofi· Source

• Recruiting

  Study to Evaluate the Pharmacodynamics, Safety and Efficacy of SKY-0515 in Participants With Huntington's Disease

  NCT07378644· Phase 2/3· Skyhawk Therapeutics, Inc.· Source

• Recruiting

  A Clinical Study of Islatravir and Ulonivirine for People With HIV-1 Who Have Not Been Treated Before (MK-8591B-062)

  NCT07266831· Phase 2/3· Merck Sharp & Dohme LLC· Source

• Recruiting

  Beginning Radiation Immediately With GammaTile at GBM Excision Versus Standard of Care

  NCT07195591· Phase 3· GT Medical Technologies, Inc.· Source

• Recruiting

  A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer

  NCT07276399· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer

  NCT07213674· Phase 3· Amgen· Source

• Recruiting

  Comparison of Intravesical Therapy and Surgery as Treatment Options for Bladder Cancer 2

  NCT07225127· University of Washington· Source

• Recruiting

  A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

  NCT06793215· Phase 3· Hoffmann-La Roche· Source

• Recruiting

  A Study of SGT-212 Gene Therapy in Friedreich's Ataxia

  NCT07180355· Phase 1· Solid Biosciences Inc.· Source

• Recruiting

  Motor-voice Assessment in Infants (MAMI)

  NCT06807203· Ohio State University· Source

• Recruiting

  A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)

  NCT07221500· Phase 2· Nurix Therapeutics, Inc.· Source

• Active, not recruiting

  Sparsentan in Posttransplant Immunoglobulin A Nephropathy or Focal Segmental Glomerulosclerosis

  NCT07219121· Phase 4· Travere Therapeutics, Inc.· Source

• Active, not recruiting

  Clinical Study of Neflamapimod in Patients With Primary Progressive Aphasia

  NCT07033481· Phase 2· EIP Pharma Inc· Source

• Recruiting

  A Study of ROC-101 in Patients With Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated With Interstitial Lung Disease (ILD-PH) (ROCSTAR STUDY)

  NCT07175038· Phase 2· AllRock Bio, Inc.· Source

• Recruiting

  Anti-inflammatory Activities of Vitamin C Supplementation on the Gut Barrier Function in Adults With Obesity

  NCT07151105· Ohio State University· Source

Showing 50 of 316.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Lung cancer16 recruiting
• Childhood cancers9 recruiting
• Head and neck cancer9 recruiting
• Alzheimer disease8 recruiting
• Acute myeloid leukaemia7 recruiting
• Bladder cancer7 recruiting
• Coronary artery disease7 recruiting
• Depression7 recruiting
• Prostate cancer7 recruiting
• Type 1 diabetes7 recruiting
• Melanoma6 recruiting
• Multiple myeloma6 recruiting
• Myeloproliferative neoplasms6 recruiting
• Osteoarthritis6 recruiting
• Pancreatic cancer6 recruiting
• Parkinson disease6 recruiting
• Colorectal cancer5 recruiting
• Myelodysplastic syndromes5 recruiting
• Ovarian cancer5 recruiting
• Stroke5 recruiting
• Chronic lymphocytic leukaemia4 recruiting
• Huntington's disease4 recruiting
• Sarcoma4 recruiting
• Spinal cord injury4 recruiting
• Triple-negative breast cancer4 recruiting
• Autism3 recruiting
• Diffuse large B-cell lymphoma3 recruiting
• Gastric and oesophageal cancer3 recruiting
• Glioblastoma3 recruiting
• Heart failure3 recruiting
• High blood pressure3 recruiting
• HIV3 recruiting
• Sickle cell disease3 recruiting
• Acute lymphoblastic leukaemia2 recruiting
• ALS (motor neurone disease)2 recruiting
• Amyloidosis2 recruiting
• Atrial fibrillation2 recruiting
• Cerebral palsy2 recruiting
• COPD2 recruiting
• Epilepsy2 recruiting
• Follicular lymphoma2 recruiting
• Friedreich ataxia2 recruiting
• Hearing loss2 recruiting
• Idiopathic pulmonary fibrosis2 recruiting
• Insomnia2 recruiting
• Kidney cancer2 recruiting
• Multiple sclerosis2 recruiting
• Myasthenia gravis2 recruiting
• Neuroendocrine tumours2 recruiting
• Obesity2 recruiting
• Type 2 diabetes2 recruiting
• ANCA-associated vasculitis1 recruiting
• Aplastic anaemia1 recruiting
• Bipolar disorder1 recruiting
• Brain aneurysm1 recruiting
• Bronchiectasis1 recruiting
• Chronic kidney disease1 recruiting
• Chronic myeloid leukaemia1 recruiting
• Congenital heart disease1 recruiting
• Crohn's disease1 recruiting
• Cystic fibrosis1 recruiting
• Dermatomyositis and polymyositis (myositis)1 recruiting
• Dilated cardiomyopathy1 recruiting
• Down syndrome1 recruiting
• Endometrial cancer1 recruiting
• Frontotemporal dementia1 recruiting
• Gout1 recruiting
• Hydrocephalus1 recruiting
• Lewy body dementia1 recruiting
• Liver and biliary tract cancer1 recruiting
• Macular degeneration1 recruiting
• Mantle cell lymphoma1 recruiting
• Meningioma1 recruiting
• Mesothelioma1 recruiting
• Metastatic breast cancer1 recruiting
• Multiple system atrophy1 recruiting
• Osteoporosis1 recruiting
• Polycystic kidney disease1 recruiting
• Polycystic ovary syndrome1 recruiting
• Pulmonary arterial hypertension1 recruiting
• Rheumatoid arthritis1 recruiting
• Schizophrenia1 recruiting
• Ventricular tachycardia1 recruiting

Closed trials

• Withdrawn

  Repeated Neurocognitive Measurements in Depressed Patients

  NCT05991232· Phase 1/2· Jay Fournier· Source

• Completed

  A Study of ONO-2020 in Participants With Mild to Moderate Alzheimer's Disease

  NCT06881836· Phase 2· Ono Pharmaceutical Co., Ltd.· Source

• Completed

  Innovative Automated Insulin Delivery System for Type 2 Diabetes

  NCT06853990· Deka Research and Development· Source

• Terminated

  BSB-1001 in Patients Undergoing HLA-Matched Allogenic Hematopoietic Stem Cell Transplant for AML, ALL or MDS

  NCT06704152· Phase 1/2· BlueSphere Bio, Inc· Source

• Completed

  A Study to Assess the Efficacy, Safety and Tolerability of VLS-01 Buccal Film, Compared to Placebo in Patients With Treatment Resistant Depression (ELUMINA)

  NCT06524830· Phase 2· atai Therapeutics, Inc.· Source

• Recruiting

  Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial)

  NCT06371417· Phase 1· Chugai Pharmaceutical· Source

• Completed

  A Retrospective Chart Review Study of Patients With CLAD-BOS Post Lung Transplantation

  NCT06503770· Zambon SpA· Source

• Completed

  VOLT-AF IDE Clinical Study

  NCT06223789· Abbott Medical Devices· Source

• Completed

  Feasibility and Acceptability of Incorporating Smartwatches Into an Exercise is Medicine Program in Older Individuals

  NCT06287255· Ohio State University· Source

• Recruiting

  A Multicenter Trial Assessing the Impact of Lipoprotein(a) Lowering With Pelacarsen (TQJ230) on the Progression of Calcific Aortic Valve Stenosis

  NCT05646381· Phase 2· Novartis Pharmaceuticals· Source

• Completed

  Effect of Moderate Renal Impairment and Race/Ethnicity on Treosulfan Pharmacokinetics

  NCT05534620· Phase 1· medac GmbH· Source

• Recruiting

  BradycArdia paCemaKer With AV Interval Modulation for Blood prEssure treAtmenT

  NCT06059638· Orchestra BioMed, Inc· Source

• Completed

  A Study of the THERMOCOOL SMARTTOUCH Surround Flow (SF) Catheter With the TRUPULSE Generator for Treatment of Drug Refractory Symptomatic PAF

  NCT06144632· Biosense Webster, Inc.· Source

• Completed

  Inspiratory Muscle Training in Obese Breast Cancer Survivors

  NCT05193149· Ohio State University Comprehensive Cancer Center· Source

• Recruiting

  A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.

  NCT06022029· Phase 1· OncoNano Medicine, Inc.· Source

• Terminated

  Open-Label Study of the CDK4/6 Inhibitor SPH4336 in Subjects With Locally Advanced or Metastatic Liposarcomas

  NCT05580588· Phase 2· Shanghai Pharma Biotherapeutics USA Inc.· Source

• Completed

  Black Impact: The Mechanisms Underlying Psychosocial Stress Reduction in a Cardiovascular Health Intervention

  NCT06055036· Ohio State University· Source

• Completed

  Use of a Screening Tool to Describe HIV-Related Cancer Burden and Patient Characteristics in the AMC

  NCT05510908· AIDS Malignancy Consortium· Source

• Completed

  RewinD-LB - Clinical Study of Neflamapimod in Patients With Dementia With Lewy Bodies

  NCT05869669· Phase 2· EIP Pharma Inc· Source

• Completed

  Respiratory Effects of E-Cigarettes in Obese Youth

  NCT05869318· Ohio State University Comprehensive Cancer Center· Source

• Withdrawn

  Telemonitoring to Treat Group 2 Pulmonary Hypertension

  NCT04882774· Phase 2· Mardi Gomberg -Maitland MD, MSc· Source

• Completed

  Re-Ablation Using a Tailored Approach Targeting EGM-Dispersion

  NCT05477147· Volta Medical· Source

• Completed

  Mentoring to be Active for Rural Appalachia Children

  NCT05758441· Ohio State University· Source

• Completed

  Stress and Hypertension in Dementia Caregivers

  NCT05721482· Ohio State University· Source

• Terminated

  Study of Covalent Menin Inhibitor BMF-219 in Adult Patients With KRAS Driven Non-Small Cell Lung Cancer, Pancreatic Cancer, and Colorectal Cancer

  NCT05631574· Phase 1· Biomea Fusion Inc.· Source

• Completed

  Evaluating a Web Delivered Behavioral Parent Training Intervention for Rural Parents of Children With Autism Spectrum Disorder

  NCT05554198· Ohio State University· Source

• Completed

  A Trial of the Safety and Efficacy of SEP-363856 in the Treatment of Adults With Major Depressive Disorder

  NCT05593029· Phase 2· Otsuka Pharmaceutical Development & Commercialization, Inc.· Source

• Terminated

  Open-label Extension for Phase 3 Clinical Trials of Simufilam

  NCT05575076· Phase 3· Cassava Sciences, Inc.· Source

• Completed

  Study of the Safety and Neuroprotective Capacity of Scp776 in Acute Ischemic Stroke

  NCT05585606· Phase 2· Silver Creek Pharmaceuticals· Source

• Completed

  A Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Active Idiopathic Inflammatory Myopathy.

  NCT05523167· Phase 2/3· argenx· Source

• Completed

  DORAYA-HF Early Feasibility Study

  NCT05206422· Revamp Medical Inc.· Source

• Completed

  A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder

  NCT04919512· Phase 2· Janssen Research & Development, LLC· Source

• Completed

  A Biomarker-Guided, Randomized, Placebo-Controlled Efficacy and Safety Study of Liafensine in Patients With TRD

  NCT05113771· Phase 2· Denovo Biopharma LLC· Source

• Terminated

  Ultrafiltration Versus IV Diuretics in Worsening Heart Failure

  NCT05318105· Nuwellis, Inc.· Source

• Completed

  A Study of JNJ-55308942 in the Treatment of Bipolar Depression

  NCT05328297· Phase 2· Janssen Pharmaceutica N.V., Belgium· Source

• Completed

  Study to Evaluate the Safety, Tolerability and Efficacy of CT1812 in Subjects With Mild to Moderate Dementia With Lewy Bodies

  NCT05225415· Phase 2· Cognition Therapeutics· Source

• Terminated

  Open-Label Extension of the PTI-125-04 Study in Mild-to-Moderate Alzheimer's Disease

  NCT05352763· Phase 2· Cassava Sciences, Inc.· Source

• Completed

  Dilated Versus Non-Dilated Wavefront Corrections for Patients With Down Syndrome

  NCT05059041· Phase 2· Ohio State University· Source

• Completed

  Activity Level Monitoring Study

  NCT05379088· Ohio State University· Source

• Completed

  AN INTERNATIONAL, OBSERVATIONAL, BLINDED STUDY TO ASSESS THE PERFORMANCE OF THE CORDIO HEARO SYSTEM

  NCT06378632· Cordio Medical· Source

• Completed

  A 12-Week Crossover Study to Assess the Efficacy, Safety and Tolerability of L1-79 in Subjects Aged 12-21 Years With Autism Spectrum Disorder

  NCT05067582· Phase 2· Yamo Pharmaceuticals LLC· Source

• Terminated

  Simufilam 50 mg or 100 mg for Mild-to-Moderate Alzheimer's Disease

  NCT05026177· Phase 3· Cassava Sciences, Inc.· Source

• Terminated

  A Trial to Evaluate the Efficacy and Safety of PQ912 in Patients With Early AD

  NCT03919162· Phase 2· Vivoryon Therapeutics N.V.· Source

• Terminated

  Study of Magrolimab Combinations in Patients With Relapsed/Refractory Multiple Myeloma

  NCT04892446· Phase 2· Gilead Sciences· Source

• Completed

  Move to Improve: Telehealth Exercise to Music for HD

  NCT05270681· Ohio State University· Source

• Completed

  Auditory Neural Function in Implanted Patients With Usher Syndrome

  NCT04906135· Ohio State University· Source

• Completed

  Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy

  NCT04985760· Phase 1· Madhu Chhanda Choudhary· Source

• Recruiting

  JAGUAR Trial: ObJective Analysis to GaUge EVAR Outcomes Through Randomization

  NCT05064540· Endologix· Source

• Terminated

  A Study Evaluating Safety, PK, and Efficacy of Tafasitamab and Parsaclisib in Participants With Relapsed/Refractory Non Hodgkin Lymphoma (R/R NHL) or Chronic Lymphocytic Leukemia (CLL)

  NCT04809467· Phase 1/2· Incyte Corporation· Source

• Completed

  Aquatic Therapy for ASD

  NCT05092321· Ohio State University· Source

Showing 50 of 146.

Conditions

Diseases this institution publishes on or runs trials for.

• Obesity168 works · 11 trials
• Lung cancer142 works · 30 trials
• Heart failure133 works · 18 trials
• HIV84 works · 8 trials
• Sarcoma78 works · 15 trials
• Colorectal cancer74 works · 10 trials
• Ovarian cancer71 works · 10 trials
• Melanoma69 works · 13 trials
• Epilepsy66 works · 4 trials
• Pancreatic cancer57 works · 13 trials
• Acute myeloid leukaemia53 works · 20 trials
• Asthma50 works · 0 trials
• Kidney cancer47 works · 8 trials
• Endometrial cancer47 works · 2 trials
• Multiple myeloma42 works · 14 trials
• Glioblastoma42 works · 7 trials
• Triple-negative breast cancer42 works · 7 trials
• Cystic fibrosis41 works · 1 trial
• Congenital heart disease39 works · 1 trial
• Schizophrenia38 works · 1 trial
• Head and neck cancer37 works · 22 trials
• Osteoarthritis36 works · 10 trials
• Duchenne muscular dystrophy34 works · 0 trials
• Sickle cell disease32 works · 6 trials
• Hodgkin lymphoma30 works · 3 trials
• Cervical cancer28 works · 3 trials
• Hearing loss27 works · 2 trials
• Childhood cancers27 works · 19 trials
• Spinal cord injury25 works · 4 trials
• Lupus (SLE)24 works · 2 trials